文献速递妇科

Gemogenovatucel-T(Vigil)免疫治疗在同源重组修复 proficient(HRP)卵巢癌中显示临床获益

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-03-11

该研究基于2b期VITAL试验的事后分析,评估Vigil在HRP卵巢癌患者中的临床获益。结果显示,与安慰剂相比,Vigil显著改善HRP患者的无复发生存期(HR=0.386;90% CI 0.199-0.750;p=0.007)和总生存期(HR=0.342;90% CI 0.141-0.832;p=0.019)。

要点

  • Vigil在HRP卵巢癌患者中显著改善无复发生存期。
  • Vigil在HRP卵巢癌患者中显著改善总生存期。
  • HR状态检测使用MyChoice®CDx评分(<42为HRP)。

核心结论

  • Vigil在HRP分子特征患者中表现出临床获益。

研究设计与样本

  • 2b期双盲安慰剂对照试验的事后分析,纳入完全缓解的III/IV期高级别浆液性、子宫内膜样或透明细胞卵巢癌患者。
  • HR状态通过MyChoice®CDx评分确定(<42为HRP),HRP患者中Vigil组25例,安慰剂组20例。

主要发现

  • HRP患者中,Vigil组相比安慰剂组无复发生存期改善(HR=0.386;90% CI 0.199-0.750;p=0.007),RMST验证p=0.017。
  • HRP患者中,Vigil组相比安慰剂组总生存期获益(HR=0.342;90% CI 0.141-0.832;p=0.019),RMST验证p=0.008。

关键数值与推荐

  • HRP定义为MyChoice®CDx评分<42。
  • 无复发生存期HR=0.386(90% CI 0.199-0.750;p=0.007)。
  • 总生存期HR=0.342(90% CI 0.141-0.832;p=0.019)。

临床怎么用

  • 对于HRP的III/IV期卵巢癌完全缓解患者,Vigil可能提供无复发生存和总生存获益。

局限性

  • 该分析为事后分析,样本量较小(Vigil组25例,安慰剂组20例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recently, Vigil showed significant clinical benefit with improvement in relapse free (RFS) and overall survival (OS) in pre-planned subgroup analysis in stage III/IV newly diagnosed ovarian cancer patients with BRCA wild type (BRCA-wt) molecular profile. Here we analyze homologous recombination (HR) status of patients enrolled in the Phase 2b VITAL study and determine clinical benefit of Vigil in HR proficient (P) patients. METHODS: Patients were previously enrolled in a Phase 2b, double-blind, placebo-controlled trial. All were in complete response with Stage III/IV high grade serious, endometroid or clear cell ovarian cancer. HR status was determined using MyChoice®CDx score (<42 = HRP) (Myriad Genetics, Inc., UT). Post-hoc analyses were carried out using Kaplan Meier and restricted mean survival time (RMST) analysis to evaluate RFS and OS based on HR deficiency (D) status. RESULTS: RFS was improved with Vigil (n = 25) in HRP patients compared to placebo (n = 20) (HR = 0.386; 90% CI 0.199-0.750; p = 0.007), results were verified by RMST (p = 0.017). Similarly, OS benefit was observed in Vigil group compared to placebo (HR = 0.342; 90% CI 0.141-0.832; p = 0.019). Results with OS were also verified with RMST (p = 0.008). CONCLUSION: Vigil exhibited clinical benefit in HRP molecular profile patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rocconi RP, Monk BJ, Walter A, et al. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecol Oncol. 2021. PMID: 33715892. doi:10.1016/j.ygyno.2021.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。